Gastrointestinal Cancer Archives | VJOncology

The GI Cancer Channel on VJOncology is supported by Seagen. This supporter has no influence over the production of the content.

View overview page

Phase I trial of mRNA neoantigen vaccines for pancreatic cancer

Vinod P. Balachandran • 16 Jun 2022

Development of individualized mRNA neoantigen vaccines for pancreatic cancer

Vinod Balachandran • 16 Jun 2022

Potential of immunotherapy for pancreatic cancer

Vinod P. Balachandran • 16 Jun 2022

Next steps for the development of individualised mRNA neoantigen vaccines

Vinod P. Balachandran • 16 Jun 2022

Salvage CT041 CLDN18.2-specific CAR T-cell therapy for patients with advanced GI malignancies

Gregory P. Botta • 13 Jun 2022

Expanding indications for a CLDN18.2-specific CAR T-cell therapy in GI cancers

Gregory P. Botta • 13 Jun 2022

Safety and efficacy of a CLDN18.2-specific CAR T-cell therapy in GI adenocarcinoma

Gregory P. Botta • 13 Jun 2022

Future directions for CLDN18.2-specific CAR T-cell therapy in GI cancers

Gregory P. Botta • 13 Jun 2022

Remaining areas of unmet need for patients with locally advanced pancreatic cancer

Rainer Fietkau • 6 Jun 2022

CONKO-007: chemoradiotherapy increases rates of R0 resection in locally advanced pancreatic cancer

Rainer Fietkau • 6 Jun 2022

FOLFIRINOX, gemcitabine + paclitaxel to enhance surgery outcomes for locally advanced PC

Rainer Fietkau • 6 Jun 2022

Colorectal cancer updates at ASCO 2022

Mark Yarchoan • 5 Jun 2022

PARADIGM: Panitumumab plus mFOLFOX6 in RAS wt mCRC

Chiara Cremolini • 4 Jun 2022

How will the PARADIGM trial change the mCRC treatment landscape?

Chiara Cremolini • 4 Jun 2022

Differential treatment options for left- and right-sided mCRC

Chiara Cremolini • 4 Jun 2022

How far away are we from implementing CTC-based approaches in prostate cancer?

Anis Hamid • 6 Jun 2022

1
2
3
4
5
Next